射频热疗联合介入化疗治疗晚期大肠癌疗效分析

目的 观察射频热疗联合介入持续动脉化疗治疗晚期大肠癌的临床初步疗效。方法 对20例局部复发和伴有肝、肺、骨、腹腔、盆腔及腹股沟淋巴结转移的晚期大肠癌患者经射频热疗法联合供养靶动脉介入灌注化疗。每例患者至少进行2个周期的介入化疗联合热疗。化疗方案为第1～3天亚叶酸钙200mg／m^2静脉滴注；第1天顺氯氨铂80mg／m^2，第1～3天如肾功能改变则改用鬼臼乙叉苷60mg／m^2动脉滴注；5-氟尿嘧啶2500mg／m^2加入超液化碘油10-30ml中进行肝动脉灌注栓塞。热疗频率40．68MHz，电容式加热，电极直径20-25cm，入射功率500-800W，反射功率20-40W。插管化疗第2天开始进行热疗，每72小时1次，每次50-0min，每疗程化疗配合4～8次热疗。结果 病灶近期疗效以CT或B超检查结果作为评价标准，完全缓解0例，部分缓解14例，总有效率为70．0％。患者化疗未出现严重不良反应。热疗不良反应为局部疼痛和脂肪硬结，不需特殊处理。结论 射频热疗联合介入持续动脉化疗治疗晚期大肠癌安全、有效。

Radiofrequency hyperthermia in combination with internvention chemotherapy in the treatment of advanced colorectal cancer

Objective To observe the therapeutic efficacy of continuous arterial infusion chemotherapy combined with radiofrequency hyperthermia in the treatment of patients with advanced colorectal cancer.Methods A total of 20 advanced colorectal cancer patients with various distant metastasis were treated by the combined continuous intra-arterial infusion chemotherapy and radiofrequency hyperthermia.For the chemotherapy,a dose of 200mg/m2 surface body area of calcium folinate(CF) was given for 1 to 3 days.80mg/m2 of cisplation was infused intravenously for the first day and repalced by etoposide Vp16,60mg/m2 for 1 to 3 days in patients with renal dysfunction.For intra-arterial infusion,a dose of 500mg/m2 5-FU was given for 72 hours.For patients with liver metastases,chemoembolization(ADM 30mg/m2+MMC 6mg/m2 mixed with ultra-lique fied lipiodol) was carried out.Radiof requency hyperthermia with a frequency of 41MHz was performed on the second day after chemotherapy.Results Response rates were as sessed by CT scan and ultrasonography.The overall response rate(CR+PR) of the cases was 70.0%.No serious side effect or complication was found in the course of chemotherapy.Local pain and lipid nodule were occasionally observed in some patients after hyperthermia.Conclusion Continuous intra-arterial infusion chemotherapy in combination with radiofrequency hyperthermia is an useful and safe method for the treatment of patients with advanced colorectal cancer.